These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 4049843)

  • 21. [Seroconversion following immunization with a plasma-derived vaccine against hepatitis B: study of a 3-injection protocol (0, 1, 6 months) in Brazzaville (Congo)].
    Taty-Taty R; Saliou P; Yala F; Couroucé AM; Arthaud ML; Nerelli B; Biendo M; Wassoumbou E
    Bull Soc Pathol Exot; 1990; 83(2):155-8. PubMed ID: 2145083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B vaccine: responder status and timing of additional booster doses.
    Fagan EA; Williams R; Eddleston AL
    Lancet; 1987 Sep; 2(8558):561. PubMed ID: 2887842
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical and serological evaluation of preventive vaccination of volunteers of the high risk group with hepatitis B vaccine].
    Brzosko WJ; Laskowski ZK; Bańkowski A; Janicki P; Dabrowa A; Tkacz B; Gall W
    Pol Tyg Lek; 1986 Jul; 41(28):893-5. PubMed ID: 2945170
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunogenicity and long-term effectiveness of the hepatitis B vaccine in newborns from HBsAg-positive mothers].
    Torres JM; Bruguera M; Fos E; Mayor A; Hierro FR
    Med Clin (Barc); 1990 Sep; 95(7):247-9. PubMed ID: 2149403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Active preventive vaccination against hepatitis B].
    Jilg W
    Internist (Berl); 1985 Oct; 26(10):633-9. PubMed ID: 2934346
    [No Abstract]   [Full Text] [Related]  

  • 26. [Inoculation against hepatitis B. Vaccines, mechanism of action, duration of the inoculation protection and revaccination].
    Jilg W
    Dtsch Med Wochenschr; 1989 Apr; 114(15):596-8. PubMed ID: 2649350
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunogenicity and tolerance of a combined hepatitis A/B vaccine. Preliminary results with a candidate vaccine].
    Kallinowski B; Bock HL; Clemens R; Theilmann L
    Dtsch Med Wochenschr; 1995 Oct; 120(42):1426-9. PubMed ID: 7555671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.
    Hadler SC; Francis DP; Maynard JE; Thompson SE; Judson FN; Echenberg DF; Ostrow DG; O'Malley PM; Penley KA; Altman NL
    N Engl J Med; 1986 Jul; 315(4):209-14. PubMed ID: 2941687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy.
    Weitberg AB; Weitzman SA; Watkins E; Hinkle C; O'Rourke S; Dienstag JL
    J Clin Oncol; 1985 May; 3(5):718-22. PubMed ID: 3158725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B vaccines--to switch or not to switch.
    Hollinger FB
    JAMA; 1987 May; 257(19):2634-6. PubMed ID: 2952813
    [No Abstract]   [Full Text] [Related]  

  • 32. [Results of an anti-hepatitis-B vaccination in a population at risk].
    Stellato M; Carbi S; Tosolini S
    Boll Ist Sieroter Milan; 1989; 68(1):34-41. PubMed ID: 2535244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Long-term follow-up study of HBsAb titers in subjects given HB vaccine and timing for additional vaccination].
    Nakao M; Yamada H; Ono T; Kuroki T; Kobayashi K; Yamamoto S; Monna T
    Nihon Shokakibyo Gakkai Zasshi; 1988 Jan; 85(1):20-7. PubMed ID: 2967388
    [No Abstract]   [Full Text] [Related]  

  • 34. [Current status and outlook of the artificial-active immunoprophylaxis of viral hepatitis B].
    Ivan A; Mitroi I
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(3):455-8. PubMed ID: 3074433
    [No Abstract]   [Full Text] [Related]  

  • 35. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations.
    Hollinger FB
    Am J Med; 1989 Sep; 87(3A):36S-40S. PubMed ID: 2528297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence and boosting response of antibody to HBsAg induced by vaccine treatment.
    Chung WK
    Trop Gastroenterol; 1988; 9(1):26-30. PubMed ID: 3420689
    [No Abstract]   [Full Text] [Related]  

  • 37. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine.
    Weber DJ; Rutala WA; Samsa GP; Santimaw JE; Lemon SM
    JAMA; 1985 Dec; 254(22):3187-9. PubMed ID: 2933532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific lymphocyte proliferative response in vitro after cDNA HBsAg immunization.
    Degrassi A; Mariani E; Roda P; Miniero R; Capelli M; Honorati MC; Astaldi A; Facchini A
    Adv Exp Med Biol; 1989; 257():237-45. PubMed ID: 2533459
    [No Abstract]   [Full Text] [Related]  

  • 39. [Vaccines against hepatitis B].
    Viazov SO
    Vopr Virusol; 1984; 29(6):656-63. PubMed ID: 6396952
    [No Abstract]   [Full Text] [Related]  

  • 40. [Long-term immunogenicity of hepatitis B vaccine in the neonate and children at risk: antibody levels and indications for booster doses].
    Corbella E; Garghetti L; Poloniato A; Zambelloni C; Consonni A
    Minerva Pediatr; 1987 Oct; 39(20):821-6. PubMed ID: 2963953
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.